Loading
Everything in development, the open problems and what is being done about them, the roadmaps, and what changed on this record.
What is in development for Non-metastatic castration-resistant prostate cancer, drawn from the whole corpus: 3 items. Drugs are grouped by the most advanced trial phase they have reached anywhere; approved treatments sit under standard of care. Technologies are the methods being tested for this cancer, trials are the studies recorded here, and ideas are proposals not yet in a trial.
Whether PSMA PET-detected metastases should be treated locally or the man treated as metastatic.
Nothing recorded yet.
Also on OnCo: Atlas of advanced disease · How cancer spreads: the metastasis stages.
Cost and side effects of years of androgen receptor inhibition in men without symptoms.
No trial compares the three drugs head to head.
Dated changes read from the records linked to this cancer: approvals, regulatory steps, reported trials, guideline versions and milestones. Newest first; no date is inferred.
On EdgeAll 10 changes by month →When this page itself was last checked or edited.
A milestone in how this cancer is treated.
Non-metastatic CRPC
Darolutamide lengthened metastasis-free and overall survival compared with placebo with a near-placebo side-effect profile; approved in July 2019.
A milestone in how this cancer is treated.
Non-metastatic CRPC (SPARTAN)